“The global oligonucleotide synthesis market projected to grow at a CAGR of 10.9%.”
The global oligonucleotide synthesis market is expected to reach USD 2.46 billion by 2022 from USD 1.47 billion in 2017 at a CAGR of 10.9%. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.
Growth in this market is mainly driven the increasing R&D expenditure by pharmaceutical and biotechnology companies, rising demand for synthesized oligonucleotides from the growing field of molecular diagnostics, rising venture capital investments, and increasing demand for synthetic genes. However, the price erosion of synthesized oligos and lack of regulations for therapeutic oligos are some factors that may hinder the growth of this market.
“Synthesized oligonucleotides are expected to grow at the highest CAGR during the forecast period.”
Based on product, the market is segmented into synthesized oligonucleotides, reagents, and equipment. The synthesized oligonucleotides segment is expected to grow at the highest CAGR during the forecast period The increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics is a key market driver in this segment. The rising availability and demand for custom oligos also contribute to the growth of the synthesized oligonucleotides market.
“The research segment is expected to hold the largest share of the market in 2017.”
Based on application, the market is segmented into research, diagnostics, and therapeutics. The research segment is estimated to hold the largest share of the oligonucleotide synthesis market in 2017. The market growth for research applications is mainly driven by the developments in the fields of gene synthesis and NGS. Oligos are widely used in technologies such as PCR, qPCR, gene synthesis, isothermal nucleic acid amplification technology (INAAT), microarray, hybridization, DNA sequencing, and next-generation sequencing (NGS).
“Academic research institutes are expected to dominate the market during the forecast period.”
Based on end user, the market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and other end users. The academic research institutes segment is expected to dominate the market during the forecast period. With the increasing funding pouring into institutes to conduct research, the demand for oligonucleotides is bound to increase. To meet this need, companies are launching products and entering into agreements with different research institutes to supply oligonucleotides for research purposes. For instance, in August 2015, Eurofins Genomics launched NGS tests for the identification of non-targeted microorganisms, including 16S Microbiome Profiling for academia and research.
“APAC to witness the highest growth during the forecast period.”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia Pacific is expected to register the highest CAGR during the forecast period. This can be attributed to factors such as the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 - 46%; Tier 3 - 18%.
• By Designation: C-level- 26%; D-level- 45%; Others- 29%.
• By Region: North America-41%; Europe-31%; Asia Pacific-20%; Latin America- 5%, Middle East and Africa-3%
List of companies profiled in the report
• Agilent Technologies (US)
• ATDBio (UK)
• Bio-Synthesis (US)
• BioAutomation (US)
• LGC Biosearch Technologies (US)
• Eurofins Genomics (Germany)
• Eurogentec (Belgium)
• GeneDesign (Japan)
• GE Healthcare (US)
• GenScript (US)
• Integrated DNA Technologies (IDT) (US)
• Nitto Denko Avecia (US)
• Thermo Fisher Scientific (US)
• TriLink Biotechnologies (US)
• Sigma-Aldrich Corporation (Sigma-Aldrich) (US) (part of Merck KGAA (Germany)
The report provides an overview of the oligonucleotide synthesis market. It aims at estimating the market size and future growth potential of this market across different segments such as product, application, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall oligonucleotide synthesis market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also will also help stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.